Synthetic control arms explained: what they mean for placebo assignment in a clinical trial

A common concern for people considering a clinical trial is the possibility of being assigned to a placebo group and receiving no active treatment. In recent years, a different kind of trial design has drawn attention for a specific reason: it can reduce, and in some cases eliminate, the use of a placebo. This design uses what is called a synthetic control arm.

The term sounds technical, and it is often misunderstood. A synthetic control arm does not involve computer-generated patients or fabricated data. It is a comparison group built from real health information collected outside the current trial. Understanding what this design is, how it works, and when it applies is useful for anyone weighing whether to enroll in a study.

What a control group does in a clinical trial

Every clinical trial that tests a new treatment needs a way to measure whether that treatment actually works. Researchers do this by comparing two groups: one that receives the investigational product (the treatment being studied) and another that does not. The second group is called the control group, or control arm.

The control group can be structured in different ways. In some studies, it receives a placebo, which is an inactive substance made to look like the real treatment but with no therapeutic effect. In other studies, the control group receives the standard of care, meaning the current accepted treatment for that condition. Assignment to the treatment group or the control group is usually decided by randomization, a process that places participants into groups purely by chance so that the two groups are as similar as possible at the start of the study.

This structure, known as a randomized controlled trial, is widely regarded by regulators such as the U.S. Food and Drug Administration as the most rigorous method for evaluating a new intervention. It is the design most participants encounter, and it is the source of the familiar question: will I receive the investigational product or a placebo?

For a closer look at how placebos and control groups function during a study, see Placebos and Controls: What It Means in Your Study.

What a synthetic control arm actually is

A synthetic control arm, more accurately called an external control arm, is a comparison group that is not made up of newly enrolled trial participants. Instead, it is assembled from health information that already exists. That information comes from people who were treated in earlier clinical trials, from patients whose care was documented in medical records, or from disease registries that track how a condition typically progresses over time.

One point deserves emphasis, because it is the most common source of confusion. The word synthetic does not mean the comparison group is fake, imaginary, or generated by a computer. The patients whose data is used are real people. Their health outcomes were recorded during real medical care or during earlier research. The word synthetic refers to how the group is assembled, using existing data rather than a newly recruited cohort, not to the nature of the patients themselves.

In practical terms, when a trial uses an external control arm, no one is enrolled specifically to serve as a placebo comparison. The comparison exists as data that has already been collected.

For a broader introduction to how clinical research is structured, see Clinical Research Basics: What Every Trial Participant Should Understand Before Enrolling.

How a synthetic control arm is built

Building an external control arm is a careful statistical process. Researchers draw on several types of existing data, depending on what is available for the condition being studied.

Historical clinical trial data is one source. Records from earlier studies, stripped of information that could identify individual patients, can supply a large pool of people who received a placebo or standard treatment in the past. Real-world data is another source. This term refers to health information collected during routine medical care, including electronic health records maintained by hospitals and clinics, insurance claims, and disease registries that follow patients with a specific condition over time. Natural history studies form a third source. These are studies that observe how a disease progresses in patients who are not receiving the new intervention, and they are especially valuable in rare conditions where little is otherwise known.

Once the data is gathered, researchers use statistical techniques to make the external group resemble the group of participants who will receive the investigational product. The most widely used method is called propensity score matching. In simple terms, each patient in the external data is scored on a set of characteristics such as age, disease severity, prior treatments, and other relevant factors. Trial participants are then paired with patients from the external data who have similar scores. The goal is to compare two groups that are as alike as possible at the starting point, so that any difference in outcomes can be attributed to the intervention rather than to underlying differences between the groups.

Technology also plays a role in how outside health data is collected and used in modern research, a topic explored in Wearables, Sensors and ePROs: Technology in Clinical Trials.

Does a synthetic control arm mean no placebo?

This is the question most participants want answered directly, and the honest answer depends on how the specific trial is designed. There are two main possibilities.

The first is a single-arm trial with an external control. In this design, every enrolled participant receives the investigational product, and the comparison group exists entirely as external data. No participant is assigned to a placebo, because there is no placebo group inside the trial itself. This is the design that genuinely eliminates the placebo question for enrollees.

The second is a hybrid design, sometimes called an augmented control design. In this design, participants are still randomized, and a placebo or standard-of-care group still exists inside the trial. External data is used to make that internal control group smaller, which means fewer participants may be assigned to placebo, but the possibility does not disappear. A participant considering such a trial could still receive a placebo.

The only reliable way to know which design a specific trial uses is to read the informed consent document carefully and to ask the study coordinator directly. A trial that is described as single-arm and externally controlled will not use a placebo. A trial that is described as randomized, even one that mentions an external control component, will.

For a closer comparison of trial participation and existing medical care, see Clinical Trial vs Standard Care: What Patients Should Know.

Where synthetic control arms are used most often

External control arms are not used in every therapeutic area. They tend to appear in situations where a traditional randomized trial is difficult, impractical, or ethically problematic.

Rare diseases are one of the most common settings. When a condition affects only a small number of people, filling a large randomized control group can be nearly impossible. Using existing natural history data as the comparison allows researchers to move forward without needing to find additional patients to serve as controls.

Oncology, the study of cancer, is another frequent setting. Single-arm cancer trials are common when the treatment being studied is expected to produce clear, measurable effects such as tumor shrinkage that would not occur without an intervention. External data can provide a meaningful benchmark for such outcomes.

Pediatric trials, meaning studies that enroll children, also use these designs more often than adult trials. U.S. regulations place strict limits on the risk to which children can be exposed in research, and assigning a child to a placebo raises heightened ethical concerns. External and natural history controls offer an alternative that avoids withholding a potentially beneficial study intervention from a child.

The common thread across these settings is that a traditional placebo group is either difficult to assemble or difficult to justify ethically. External control arms are chosen because they answer a genuine problem, not because they are considered a general substitute for randomized trials.

What synthetic control arms cannot replace

External control arms have real advantages, but they also have real limitations, and regulators are careful about how much weight they place on this kind of evidence.

The central scientific concern is bias. Because participants are not randomly assigned between the treatment group and the external group, the two groups may differ in ways that were never measured. Statistical matching can adjust for characteristics that are recorded, but it cannot adjust for factors no one thought to record. That unmeasured difference can distort the apparent effect of the intervention.

Data quality is a second concern. Health information collected during routine medical care is not always complete, consistent, or recorded in the same way across different sources. Outcomes measured in ordinary practice may not match the precise definitions used in a trial. Older data may reflect a version of standard care that has since improved, which can make the treatment being studied look more effective than it actually is.

Regulatory acceptance is also evolving. The FDA has issued draft guidance describing how it evaluates externally controlled trials, and it treats each submission case by case. The agency has stated that in many situations the chance of credibly demonstrating that a treatment works using an external control is low, and that sponsors should choose a more suitable design when possible. Randomized controlled trials remain the standard against which other designs are measured.

Understanding common misconceptions about clinical research helps participants weigh these tradeoffs, a topic covered in Clinical Trial Myths Busted: Facts Every Participant Should Know.

Questions to ask the study team before enrolling

A participant considering a trial that mentions an external or synthetic control arm can take a few concrete steps to understand what enrollment would actually involve.

The first step is to read the informed consent document in full. This document is required to describe the design of the study, including whether a placebo is used, how participants are assigned to groups, and what the comparison group looks like. If the language is unclear, the study coordinator is required to explain it.

The second step is to ask direct questions. Is this a single-arm trial or a randomized trial? If it is randomized, what are the chances of being assigned to placebo? What is the comparison group made up of, and where does that data come from? Who reviews the outcomes to make sure the comparison is fair? These are reasonable questions, and study teams expect them.

DecenTrialz offers a pathway that supports participants at the earliest stage of exploring a trial. After sharing basic information, a registered nurse conducts an initial pre-screening review and, if there is a potential match, refers the individual to the research site team. The research site team handles the study walk-through, final eligibility determination, informed consent, and enrollment decisions. To begin the process, visit decentrialz.com.

Taking the next step with clear information

Synthetic control arms represent one of several ways clinical research is changing to reduce placebo use and to make trials feasible in conditions where traditional designs fall short. For participants, the key point is that the design of a specific trial determines what enrollment will involve. A clear conversation with the study team, informed by the questions above, is the most reliable way to know what to expect.

DecenTrialz uses AI-assisted matching and registered nurse-led pre-screening to help potential participants explore whether a trial may be right for them.

The research site team owns eligibility determination, informed consent, study walk-through, and enrollment decisions.

To share basic information and begin an initial pre-screening review, visit decentrialz.com.